Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy-free neoadjuvant Foveciclib + AI + trastuzumab + pertuzumab in HR+/HER2+ breast cancer
ChiCTR2600126890Phase 4Not yet recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of foveciclib in breast cancer, sponsored by Ningbo No. 2 Hospital. Primary endpoint: total pathologic complete response rate (tpCR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
foveciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600126890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126890.